apoptosis and cell differentiation, in neovascularization as well as tumor cell migration and invasion into the brain parenchyma. Genetic alterations which play an important role in glioma development include a loss, mutation or hypermethylation of the tumor suppressor gene TP53 or other genes involved in the regulation of the cell cycle, such as cyclin-dependent kinase N2A/p16, p14ARF and primitive neuroectodermal tumor (PTEN), as well as activation or amplification of oncogenes and growth factors and/or their receptors, such as MDM2, cyclin-dependent kinase 4, cyclin D1 and D3, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), PDGFR [platelet-derived growth factor (PDGF) receptor], and transforming growth factor-␤. [3] [4] [5] During progression from low-grade astrocytoma (WHO grade II) to anaplastic astrocytoma (WHO grade III) and to glioblastoma multiforme (WHO grade IV) a step-wise accumulation of genetic alterations occurs. Whereas TP53 mutation and PDGF and PDGFR-␣ overexpression represent early changes during low-grade glioma development, progression to anaplastic astrocytoma is associated with pRB alteration and loss of heterozygocity (LOH) of 19q, further malignant progression to glioblastoma including LOH 10q and mutations of the PTEN gene. 6 These secondary glioblastomas, which develop from better differentiated astrocytomas, can be distinguished from primary de novo glioblastomas on the basis of molecular genetic findings 7 with amplification and/or overexpression of the EGFR, p16 deletion, PTEN mutation, pRB alteration, and LOH 10p and 10q associated with primary glioblastoma. Most importantly, molecular alterations have been identified, which indicate therapeutic response of patients and, thus, are prognostically relevant: anaplastic oligodendrogliomas with LOH 1p and/or LOH 19q are characteristically sensitive to PCV (procarbazine, lomustine, and vincristine) chemotherapy, and patients' survival is significantly prolonged. 8 -11 An overview of the tumors in the cranial cavity is given in Table 1 .
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IMAGING FOR PRIMARY DIAGNOSIS
Cranial computed tomography (CT) and magnetic resonance imaging (MRI) with and without contrast media are widely used for primary diagnosis of brain tumors. Standard T1-and T2-weighted MRIs detect brain tumors with high sensitivity. Beside primary information on the size and localization of the tumor, especially MRI provides additional information about secondary phenomena such as mass effect, edema, hemorrhage, necrosis, and signs of increased intracranial pressure at high spatial resolution and with high tissue contrast. A set of various MRI acquisitions parameters, like T1-, T2-, proton-, diffusion-, and perfusion-weighted images as well as fluid attenuated inversion recovery (FLAIR) sequences give a characteristic pattern of each tumor depending on tumor type and grade.
Most brain tumors are hypointense on T1-weighted images and hyperintense on FLAIR, T2-, and protonweighted images. Highly proliferative active tumors such as glioblastomas lead to a destruction of the blood-brain barrier (BBB) with subsequent leakage of contrast media (FIG. 1) , which is being used for diagnostic purpose in CT and T1-weighted MRI. In contrast, low-grade tumors usually have no or minimal enhancement. The contrastenhancing lesion (T1 ϩ Gd) corresponds histologically to a hypercellular region with neovascularization, a central hypointense area (T1) is mainly caused by tumor necrosis. Already in the CT-era, biopsies from signal changes in areas surrounding the contrast-enhancing tumor revealed the presence of migrating tumor cells. The tumor volume measured as the volume of T2 hyperintensity is the strongest predictor of overall survival in patients with supratentorial diffuse astrocytoma WHO°I I and the only predictor of malignant progression.
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Studies on the value of diffusion-weighted imaging (DWI) MRI are ongoing. DWI is able to characterize morphological features including edema, necrosis, and viable tumor tissue by measuring differences in the apparent diffusion coefficient (ADC). DWI might be able to detect areas of tumor infiltration which are not visible on other MRIs. 52 Furthermore, DWI seems to be useful in providing a greater degree of confidence in distinguishing brain abscesses from cystic or necrotic brain tumors than conventional MRI. 53 Moreover, dynamic contrast-enhanced MRI is a new and promising imaging tool for measuring physiological tumor properties (e.g., microvascular permeability and plasma volume ; FIG. 2) . The vascular hyperpermeability of tumor vessels for macromolecular solutes yields a proteinaceous exudate within the tumor interstitium that is considered a favorable milieu for the in-growth of new capillary buds. Changes in tumor vessel permeability and tumor volume as assessed by dynamic contrast enhanced perfusion MRI serve as surrogate marker for angiogenesis and allow the prediction of pathologic tumor grade 54,55 with high sensitivity but limited specificity.
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It should be pointed out that the different tissue compartments within a glioblastoma giving rise to different magnetic resonance signals have different gene and protein expression patterns. 59 Thus, there is potential for imaging-guided proteomics and microarray analysis to identify specific markers of tumor behavior.
Because intratumoral heterogeneity of brain tumors is not adequately reflected in conventional MRI because evaluation of the contrast enhancing lesion can either under-or overestimate the presence of active tumor, magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) are being performed to gain additional information on metabolic and molecular tumor markers. MRS gives additional information on the real extent of the tumor and on tissue metabolites, such as N-acetylaspartate (NAA), creatine, choline, and lactate. 60 The increase of choline-containing compounds and of NAA appears to correlate best with the degree of tumor infiltration.
61,62 The appearance of creatine differentiates gliomas from metastasis, which generally lack creatine. 63 An improved automated MRS analysis approach (nosologic imaging) enables correct differentiation between low-grade glioma, high-grade glioma, meningiomas, metastasis, necrosis, and healthy tissue in up to 90% of cases and shall facilitate a noninvasive diagnosis of lesion type. 64, 65 Disadvantages of MRS include its low spatial resolution, which cannot fully address the anatomical and contrast heterogeneity of brain tumors observed with MRI.
The role of PET has been primarily investigated in patients with gliomas as the most frequent and most difficult to treat primary brain tumors. PET reveals highly specific quantitative information on the metabolic state of gliomas. 66 -68 PET allows the quantitative localization of expression of endogenous or exogenous genes coding for enzymes or receptors by measuring the accumulation or binding of the respective enzyme substrates or receptor binding compounds. 69 -71 Depending on the radiotracer, various molecular processes can be visualized by PET, most of them relating to an increased cell proliferation within gliomas (FIG. 1) . F]FDG-PET depicts the rate of glucose uptake and has been used to detect the metabolic differences between normal brain tissue, low-grade and high-grade gliomas, and radionecrosis. [72] [73] [74] Increased intratumoral glucose consumption correlates with tumor grade, cell density, biological aggressiveness, and survival of patients in both primary and recurrent gliomas. 74 -79 In general, low-grade tumors have a metabolic activity similar to white matter and higher-grade tumors, similar to gray matter (FIG. 3) . A tumor-to-white matter ratio greater than 1.5 and tumor-to-gray matter ratio less than 0.6 were found to be indicative of high grade tumors with high sensitivity (94%) and limited specificity (77%). 80 Relatively benign tumors with a high FDG uptake included pilocytic astrocytoma and ganglioglioma. Pilocytic astrocytomas have a good prognosis despite exhibiting high FDG uptake and positive contrast enhancement (MRI) due to the presence of metabolically active fenestrated endothelial cells. The limited differentiation between tumor and normal gray matter by [ 18 F]FDG-PET may be improved by scanning at delayed intervals 3-7 h after tracer injection. 81 However, due to the relative high background levels of cortical glucose consumption more specific radiotracers for glioma diagnosis were developed.
The radiolabeled amino acids methyl-
18 F]-fluoroethyl)-L-tyrosine have been shown to be more specific tracers for tumor detection and tumor delineation due to their low uptake in normal brain. 21, 78, [82] [83] [84] [85] [86] The increased methionine uptake (factor of 1.3-3.5 in comparison with a contralateral control region) is related to increased transport mediated by type L amino acid carriers. 87, 88 [ 11 C]MET-uptake correlates to cell proliferation in vitro, the expression of Ki-67 and proliferating cell nuclear antigen, as well as to microvessel density, explaining its role as a marker for active tumor proliferation. 82, 89, 90 The intensity of [ 11 C]METuptake differentiates between WHO II°and WHO III°/ IV°gliomas (FIG. 3) . 21, 86 Uptake is increased not only in solid parts of the tumor but also in the infiltration area. 91, 92 100 -103 The overall goal is to be able to quantify chemotherapeutic effects early (within days to weeks).
A summary of MRI and PET findings in human brain tumors are given in Table 1 .
IMAGING FOR PLANNING RESECTION AND RADIATION THERAPY INCLUDING DELINEATION FROM FUNCTIONAL NEURONAL TISSUE
MRI is the method of choice for tumor localization. Delineation of the tumor in three dimensions (sagittal, coronal, and axial) allows the selection of the best operative procedure. CT is being used for detection of calcifications in oligodendrogliomas, meningiomas, or craniopharyngiomas and for tumors that are located at the base of the skull. Magnetic resonance angiography is being used alone or together with conventional angiography to study the location of the tumor with respect to its vascularization. In selected patients and in specialized institutions, MRS and PET are being used in conjunction with MRI to define the real extend of the tumor. 91,104 -107 Most importantly, tumors that are located in eloquent areas require preoperative functional imaging by functional MRI (fMRI) or functional PET (FIG. 4) . 108 -115 These combined imaging procedures are especially important in those patients where tumor growth has led to changes within the neuronal network as a result of functional brain plasticity. These changes consist either of a displacement of functional important neuronal tissue (like language areas) surrounding the lesion or in the recruitment of new brain areas that are usually not involved in the performance of a certain task. 114 -116 Functional imaging studies alone can provide information about which brain areas are involved in the performance of a certain behavioral task but can not answer the diagnostically important question of whether a certain brain area is essential for that task. This additional information can be obtained by combining functional brain images with transcranial magnetic stimulation, an electrophysiological method to temporarily interfere with normal brain function 116a . A distance of 1 cm or more between the functional relevant cortex, as delineated by fMRI, and the tumor significantly reduces the risk of postoperative loss of function. 117 The evaluation of the cerebral reorganization of motor function is an essential step in predicting the risk of motor deficits in patients with an indication for operative treatment. 118 Only these combined imaging technologies will allow to maximize the spatial extent of tumor treatment and to simultaneously preserve functional relevant tissue. 119 Moreover, metabolic or molecular information derived from PET or SPECT studies is being used in some institutions for the exact planning for radio- 105 and gene therapy. 120, 121 This is of special importance because tumor volume as depicted by contrast-enhanced MRI is always smaller than the tumor volume as depicted by [ 11 C]MET-PET. 97 Whether [ 11 C]MET-PET-guided extended fields of radiation have a significant influence on time to progression and overall survival has to be proven in future studies.
In recent years, diffusion tensor white matter fiber tracking and intraoperative MRI have become promising tools to guide the neurosurgeon intraoperatively. These techniques allow to maximize tumor resection without additional morbidity 122, 123 by avoiding lesions to fiber tracts like the pyramidal tract.
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IMAGING FOR PLANNING STEREOTAXIC BIOPSY AND TARGETED APPLICATION OF THERAPEUTICS
Brain tumors may consist of different parts, which are heterogenous with respect to tumor grading; thus, lowand high-grade areas may be present within the same (FIG. 5) . 120, 121 In trials employing convection-enhanced delivery of local chemotherapeutics, DWI is being used to assess the convective process and routine diagnostic MR imaging to identify the tumor response.
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IMAGING FOR DETERMINATION OF TREATMENT EFFECT, TUMOR PROGRESSION, AND DIFFERENTIATION OF RECURRENT TUMOR FROM RADIATION NECROSIS
The effects of treatment should ideally be visualized with the same imaging parameters that have been used before therapy (FIG. 5) . However, there are several limitations inherent in each imaging modality. On contrastenhanced MRI, residual tumor and postsurgical changes can both result in abnormal enhancement. Therefore, MRI cannot be used postoperatively after day 3 and for several weeks because the surgical damage of the BBB, with subsequent leakage of contrast media, leads to a false-positive indicator of the presence of residual or recurrent tumor. Moreover, conventional MRI techniques usually fail to detect early effects of radio-and chemotherapy because individual treatment effects are only visible after more than 12 months, [133] [134] [135] with a substantial interobserver variability in the assessment of treatment response. 136 Especially after the application of biologically active agents (gene therapy vectors, toxins), the value of conventional MRI to detect therapy-specific changes of tumor viability is limited 137 as reviewed previously. 138 In contrast, dynamic contrast enhanced MRI, as a surrogate marker for angiogenesis, is useful for monitoring antiangiogenic therapies in brain tumors. 139 Moreover, diffusion-weighted MRI detects therapy-induced water diffusion changes and has been suggested to provide an early surrogate marker for quantification of treatment response. 140 It was found that low values for the ADC indicating high tissue viability imply better response to radiotherapy, whereas high ADC values indicating necrosis correlate with poorer response. 141 Assessment of ADC ratios from tumor and contralateral control regions were also useful in the differentiation of radiation effects 
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(high ADC ratios) from tumor recurrence or progression (low ADC ratios). 142 However, it should be kept in mind that dexamethasone treatment significantly reduces the diffusivity of edematous brain, 143 thus confounding the interpretation of DWIs.
Because MRS can reliably differentiate pure tumor, pure necrosis, and normal tissue, specific changes in tumor metabolite levels as detected by MRS may be predictive for the effectiveness of experimental treatment strategies. 144 However, MRS alone may not be particularly helpful because most patients have mixed histological findings comprised of necrosis and tumor giving rise to inconclusive findings. In contrast, progression from low-grade to high-grade gliomas leads to a characteristically increased concentration of choline and a reduced NAA peak with high diagnostic accuracy.
Due to the relatively high cortical background activity, [ 18 F]FDG-PET is not suited to detect residual tumor after therapy. 145, 146 Similar to structural imaging, the effects of radio-and chemotherapy can be visualized by [ 18 F]FDG-PET only after several weeks 147 with a possible transient increase of [ 18 F]FDG-uptake in the initial phase which is most likely due to infiltration of macrophages consuming [ 18 F]FDG. 148 -150 At further followup, however, recurrent tumor and progression from lowgrade to high-grade glioma can be visualized by a newly appearing hypermetabolism. 151, 152 [ 18 F]FDG-PET has a sensitivity of 75% and a specificity of 81% for the detection of recurrent tumor versus radiation necrosis. 153 Moreover, in patients after stereotactic radiotherapy for brain metastasis, coregistration of [
18 F]FDG-PET images with MRI yields an improvement of the sensitivity for the detection of recurrent tumor from 65-86%. Disadvantages of [ 18 F]FDG-PET include accumulation of [ 18 F]FDG in macrophages that may infiltrate the sites having received radiation therapy. Therefore, radiation necrosis may be indistinguishable from recurrent tumor. It should be noted that in patients receiving corticosteroids as symptomatic treatment evaluation of [
18 F]FDG-PET may be hampered by a reduced cortex-to-white matter ratio. 154 [ 11 C]MET-PET in contrast is much better suited to follow the effects of radiation therapy, which show as a reduction of relative methionine-uptake, 146 which may also be observed in animal models. 149 Most importantly, [ 11 C]MET-PET successfully differentiates between recurrent tumor and radiation necrosis (FIG. 6) 155 with the detection of recurrent tumor at high sensitivity and high specificity. 
IMAGING IN EXPERIMENTAL BRAIN TUMOR MODELS
Imaging studies in experimental brain tumor models over the past 10 years aimed toward 1) the development of new radiotracers for cellular proliferation and protein synthesis, 2) characterization of these tracers with respect to their ability to detect responses to radio-and chemotherapy at a relatively early stage, 3) strategies for imaging transcriptional regulation and migration of tumor cells, and 4) imaging the expression of exogenous genes carrying a marker or therapeutic function and introduced into experimental gliomas for the purpose of developing improved gene therapeutic vectors. These experimental strategies have been reviewed in detail previously. 67 New developments aim toward 1) the detection of tumor cell migration in vivo, 160 2) the establishment of in vivo assays for direct imaging of tumor-specific signal transduction pathways (e.g., p53-, E2F-1 and HIF-1-␣ regulated pathways [161] [162] [163] [164] ), 3) the design of labeled peptides binding specifically to the cell adhesion receptor integrin ␣(v)␤ 3 or other tumor-specific antigens and of labeled bone marrow-derived endothelial precursor cells to allow highly specific tumor visualization and the study of glioma angiogenesis and neovascularization, [165] [166] [167] [168] [169] 4) the generation and in vivo characterization of transgenic mice with gliomas induced by signaling through Ras and Akt pathways, 170 and 5) the construction of bifunctional imaging marker and therapeutic genes to allow direct assessment of therapeutic gene expression in culture and in vivo models by directly corresponding assays. 171, 172 Especially the design of small tumor-specific antibody fragments is an attractive way for specific detection of Many of the current experimental protocols investigating new drug and treatment strategies for experimental gliomas include MRI, optical or PET imaging of either the distribution of therapeutic agents, [173] [174] [175] or therapyinduced tumor-changes, 171,176 -184 with the overall attempt of designing image-guided treatments. 120, 121 Most intriguing for potential clinical application is the design of multifunctional nanoparticles that can be detected both by MRI and fluorescence imaging, allowing for the noninvasive preoperative assessment of the tumor and for the intraoperative visualization of tumor margins by optical imaging.
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SUMMARY AND CONCLUSION
Multimodal imaging (CT, MRI, PET, optical) and multitracer PET imaging 1) reveal the best set of anatomical, biochemical and molecular information on a specific tumor and, hence, a noninvasive diagnosis of lesion type and grade, 2) guide therapeutic choices, and 3) assess therapy effects. It should be pointed out that these imaging modalities are not competing with each other but give complementary information on various parameters of interest. Not every patient can be studied by these imaging technologies, and it is not necessary to do so. But these imaging technologies should be used together in selected patients to advance model systems and our understanding of the complex mechanism of glioma formation, behavior and migration and to allow the development and assessment of new therapeutic modalities including molecular targeted and gene therapies ("imaging-guided therapies"). 
